1
Describing the Progression from Chlamydia trachomatis and Neisseria
gonorrhoeae to Pelvic Inflammatory Disease: Systematic Review of Mathematical Modeling Studies
Sereina A. Herzog, MSc, Janneke C.M. Heijne, MSc, Christian L. Althaus, PhD, Nicola Low, MD
Supplemental Digital Content 2
Reference list for Table 3: Sources of values used for progression to PID
2 References
S1. Marrazzo JM, Celum CL, Hillis SD et al. Performance and cost-effectiveness of
selective screening criteria for Chlamydia trachomatis infection in women. Implications for a national Chlamydia control strategy. Sex Transm Dis 1997; 24:131–41
S2. Mehta SD, Bishai D, Howell MR et al. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis 2002; 29:83–91
S3. Petitta A, Hart SM, Bailey EM. Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department. Pharmacotherapy 1999;
19:648–54
S4. Westrom L, Eschenbach D. Pelvic inflammatory disease, In: Holmes KK, ed. Sexually transmitted diseases. New York: McGraw-Hill Health Professions Division; 1999:783–
809
S5. Center for Disease Control and Prevention. Tracking the hidden epidemics: Trends in STDs in the United States, 2000. Atlanta, GA: Centers for Disease Control and Prevention; 2001
S6. Scholes D, Stergachis A, Heidrich FE et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334:1362–66 S7. Stamm WE, Guinan ME, Johnson C et al. Effect of treatment regimens for Neisseria
gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med 1984; 310:545–49
S8. Hillis SD, Joesoef R, Marchbanks PA et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168:1503–09
S9. Ness RB, Hillier SL, Kip KE et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004; 104:761–69
S10. Ness RB, Hillier SL, Kip KE et al. Douching, pelvic inflammatory disease, and incident gonococcal and chlamydial genital infection in a cohort of high-risk women. Am J Epidemiol 2005; 161:186–95
S11. Walker CK, Workowski KA, Washington AE et al. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases. Clin Infect Dis 1999; 28 Suppl 1:S29-36 S12. Beigi R, Wiesenfeld H. Pelvic inflammatory disease: new diagnostic criteria and
treatment. Obstetrics and Gynecology Clinics of North America 2003; 30:777–93 S13. Simms I, Stephenson JM. Pelvic inflammatory disease epidemiology: what do we know
and what do we need to know? Sex Transm Infect 2000; 76:80–87
S14. Rahm VA, Gnarpe H, Rosén G. Chlamydia vanligt hos tonårsflickor som söker för preventivmedelsrådgivning. Lakartidningen 1986; 83:615–16
S15. Douglas JM Jr, Newman D, Bolan G et al. Low rate of pelvic inflammatory disease (PID) among women with incident Chlamydia trachomatis (CT) infection. Int J STD AIDS 2001; 12:65–67
S16. Low N, Egger M, Sterne JAC et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study. Sex Transm Infect 2006; 82:212–18
S17. Washington AE, Johnson RE, Sanders LL. Chlamydia trachomatis infections in the United States. What are they costing us? JAMA 1987; 257:2070–72
S18. Wiesenfeld HC, Hillier SL, Krohn MA et al. Lower genital tract infection and
endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002;
100:456–63
S19. Hossain A. Chlamydia trachomatis infections. Int J Gynaecol Obstet 1989; 29:107–15 S20. Maurice J. Ubiquitous parasites: Chlamydia infections now commonest sex-transmitted
disease. Int Health Mag 1983; 3:19